i hearing new antidepressant vortioxetine marketed brand name brintellix i decided post something numerous searches resulted hits blog looking information medication consultant i probably best position start prescribing medication majority people i see already least one antidepressant typically tried many common mistakes ten years ago like inadequate dosing prevalent augmentation strategies like addition bupropion aripiprazole buspirone common primary care settings nobody uses lithium anymore apart mood disorder specialists nobody uses monoamine oxidase inhibitors i getting point i seeing people responded vilazodone nothing else seemed work even numbers low anything unique vortioxetine looking package insert approved treatment major depressive disorder nothing else date approval standard contraindications black box warning warnings antidepressants substrate cypd therefore dose needs decreased inhibitors increased inducers enzyme cytochromes cypa cypc cypc cypa cypc cypb also play minor roles metabolism metabolite inactive discontinuation symptoms also mentioned package insert citing headaches muscle tension following abrupt discontinuation manufacturer states anyone taking mg day dose decreased mg day week discontinuation done vortioxetine hour half life generally detailed pharmaceutical pharmacodynamic information recent fda approved package inserts vortioxetine exception noted graphic potent inhibitor serotonin reuptake htt sert order magnitude escitalopram pharmacology serotonin receptors right column complex i highlighted serotonin receptors vortioxetine binds kis nm drug also antagonist ht htd ht htb partial agonist hta receptor agonist values package insert serotonin pharmacology complex one review written pharmds financial conflicts interest described vortioxetine novel multimodal antidepressant agent complex mechanism action suggest pharmacodynamic profile results increased levels serotonin norepinephrine dopamine acetylcholine histamine interestingly comment greater binding affinity norepinephrine transporter net snri venlaxine snri duloxetine see table also contained package insert information serotonin receptor occupancy based imaging studies two clinical positron emission tomography pet studies using htt ligands showed occupancy doses mg day respectively clinical trials results also described package insert ere week double blind placebo controlled studies using ham madrs outcome measures six studies plotted mean change baseline plot better placebo week measurement error bar touched went past difference placebo line results maintenance study also described looked results randomizing patients remission continuation treatment vortioxetine mg day placebo survival analysis showed significantly longer remission depression vortioxetine group using effect estimation approach number needed treat harm nnt nnh nnt response nnt remission nnh review article authors describe total short term clinical trials active comparator active comparator ws duloxetine mg day venlafaxine extended release mg day comparator trials run placebo like serotonergic agents nausea diarrhea common reasons discontinuation likelihood dose dependent significant rates vs placebo sexual dysfunction measured clinical trials using arizona sexual experiences scale asex baseline rates established clinical means initial rates men women using asex rates ranged women versus placebo men versus placebo interesting side effect me headaches seven references head package insert discussions discontinuation symptoms sign hyponatremia i could find listed side effect looking review may artifact high rate headache placebo group overall rates discontinuation clinical trials compared placebo low point vortioxetine described moderately effective antidepressant purported novel mechanism action relatively limited exposure people clinical trials i expect pricing reflect usual high price novel antidepressant medication managed care pharmacy systems require prior authorization documentation medication trials failed clinicians perspective i cautious using medications potential pharmacodynamic pharmacokinetic effects disclaimer vortioxetine effect cardiac repolarization ms threshold regulatory concern deter me necessary evaluation patients taking combinations medications affect cardiac conduction present new cardiac symptoms i also try provide discussion unknowns people looking next medication might effective chronic depression i going renew membership acs access detailed discussion medicinal chemistry involved reference george dawson md dfapa brintellix vortioxetine fda approved package insert pearce ef murphy ja vortioxetine treatment depression annpharmacother jun doi epub mar pubmed pmid bang andersen ruhland rgensen smith frederiksen k jensen kg zhong nielsen sm hogg rk stensb l tb discovery dimethylphenylsulfanylphenyl piperazine lu aa novel multimodal compound treatment major depressive disorder med chem may doi jmg epub apr pubmed pmid